Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide effervescent tablet in resistant oral chronic graft versus host disease
2005-002754-22Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of budesonide in Oral chronic graft versus host disease, sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Objective response rate at final/withdrawal visit. Started Nov 2005; status: completed.
02
Drugs
budesonide
03
Conditions
Oral chronic graft versus host disease
Beyond the preview
Go deeper on 2005-002754-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002754-22.